NASDAQ:OVID - Ovid Therapeutics Stock Price, Forecast & News

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Ovid Therapeutics Inc (NASDAQ:OVID) issued its earnings results on Friday, November, 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.45) by $0.02. View Ovid Therapeutics' Earnings History.

Ovid Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Ovid Therapeutics.

8 analysts have issued 12-month price targets for Ovid Therapeutics' shares. Their forecasts range from $10.00 to $27.00. On average, they anticipate Ovid Therapeutics' stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 247.4% from the stock's current price. View Analyst Price Targets for Ovid Therapeutics.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ovid Therapeutics.

Press coverage about OVID stock has been trending negative on Sunday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ovid Therapeutics earned a coverage optimism score of -2.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Ovid Therapeutics.

Ovid Therapeutics saw a drop in short interest in November. As of November 29th, there was short interest totalling 636,400 shares, a drop of 16.4% from the November 14th total of 761,400 shares. Based on an average daily trading volume, of 743,900 shares, the days-to-cover ratio is currently 0.9 days. Approximately 3.2% of the shares of the stock are short sold. View Ovid Therapeutics' Current Options Chain.

Some companies that are related to Ovid Therapeutics include Stoke Therapeutics (STOK), CannTrust (CNTTF), Akebia Therapeutics (AKBA), Aprea Therapeutics (APRE), ANI Pharmaceuticals (ANIP), Revance Therapeutics (RVNC), Clovis Oncology (CLVS), Kiniksa Pharmaceuticals (KNSA), Dermira (DERM), Urogen Pharma (URGN), Collegium Pharmaceutical (COLL), Intra-Cellular Therapies (ITCI), Axovant Sciences (AXON), Kura Oncology (KURA) and Omeros (OMER).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Zynerba Pharmaceuticals (ZYNE), AcelRx Pharmaceuticals (ACRX), Anavex Life Sciences (AVXL), Amicus Therapeutics (FOLD), Marinus Pharmaceuticals (MRNS), Heron Therapeutics (HRTX), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE) and Verastem (VSTM).

(OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Ovid Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Granite Point Capital Management L.P. (0.90%), Redmile Group LLC (0.26%), Millennium Management LLC (0.21%), Virtu Financial LLC (0.05%) and Commonwealth Equity Services LLC (0.04%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams, Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda. View Institutional Ownership Trends for Ovid Therapeutics.

OVID stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Redmile Group LLC and Granite Point Capital Management L.P.. View Insider Buying and Selling for Ovid Therapeutics.

OVID stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC and Commonwealth Equity Services LLC. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams, Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda. View Insider Buying and Selling for Ovid Therapeutics.

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OVID stock can currently be purchased for approximately $4.03.

Ovid Therapeutics has a market capitalization of $192.71 million. The company earns $-51,980,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Ovid Therapeutics employs 55 workers across the globe.View Additional Information About Ovid Therapeutics.

The official website for Ovid Therapeutics is http://www.ovidrx.com/.

Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]